Impact of vancomycin therapeutic drug monitoring on mortality in sepsis patients across different age groups: a propensity score-matched retrospective cohort study

Description

Huaidong Peng and co-authors test whether watching blood levels of a powerful antibiotic saves lives in sepsis, and whether age changes the answer. Their 2024 study mines a large intensive care database for over fourteen thousand sepsis patients treated with vancomycin. About half had their drug levels monitored during the stay.

After matching patients on other characteristics, the monitored group died within thirty days at a clearly lower rate, about twenty-three percent against twenty-eight. Adjusted models agreed, cutting the death risk by roughly a third. The benefit appeared across age groups, with spline analysis probing how risk bends with age. Monitoring also guards kidneys by preventing overdosing, a second channel of benefit. Observational data cannot prove cause, and the authors lean on matching and sensitivity checks. Still, the scale and consistency make a practical case for routine level checks.

Catalog record

Source: https://europepmc.org/articles/PMC11669523